MASH innovator drug partnerships surge over $2.5 bn in 2024YTD: GlobalData
MASH drugs secured over $5.7 billion in total partnership deal value from 2018 to 2024YTD, where 2024YTD is already the top year…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
nonalcoholic steatohepatitis
HepaStem seems most promising pipeline agent for decompensated cirrhosis due to NASH: GlobalData
HepaStem is a stem cell therapy consisting of liver-derived mesenchymal stem cells (MSC) that addresses different components of…
NASH market holds enormous untapped potential: GlobalData
Currently, Madrigal’s resmetirom (selective thyroid hormone receptor-β agonist; THR-Beta agonist) will most likely be the first…